Bayesian hierarchical modeling based on multisource exchangeability
暂无分享,去创建一个
[1] Jonathan French,et al. Using Historical Data With Bayesian Methods in Early Clinical Trial Monitoring , 2012 .
[2] Suhail A R Doi,et al. Meta-analysis of heterogeneous clinical trials: an empirical example. , 2011, Contemporary clinical trials.
[3] Gene Pennello,et al. Experience with Reviewing Bayesian Medical Device Trials , 2007, Journal of biopharmaceutical statistics.
[4] A. Raftery. Bayesian Model Selection in Social Research , 1995 .
[5] D. Sargent,et al. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] D. Hatsukami,et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. , 2010, Addiction.
[7] Jason A. Oliver,et al. Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes , 2016, Tobacco Control.
[8] D. Madigan,et al. Bayesian Model Averaging for Linear Regression Models , 1997 .
[9] Robert E. Kass,et al. A default conjugate prior for variance components in generalized linear mixed models (comment on article by Browne and Draper) , 2006 .
[10] Edward S. Kim,et al. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.
[11] M. al’Absi,et al. Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms , 2017, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[12] Nan Chen,et al. Phase II trial design with Bayesian adaptive randomization and predictive probability , 2012, Journal of the Royal Statistical Society. Series C, Applied statistics.
[13] P. Green. Reversible jump Markov chain Monte Carlo computation and Bayesian model determination , 1995 .
[14] Jason D. Robinson,et al. Randomized Trial of Reduced-Nicotine Standards for Cigarettes. , 2015, The New England journal of medicine.
[15] A. Raftery,et al. Default Priors and Predictive Performance in Bayesian Model Averaging, with Application to Growth Determinants , 2007 .
[16] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[17] Arto Luoma,et al. Bayesian Model Selection , 2016 .
[18] Rachel S. G. Sealfon,et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. , 2014, The New England journal of medicine.
[19] Gordon Graham,et al. Bayesian sample size for exploratory clinical trials incorporating historical data , 2008, Statistics in medicine.
[20] Brian P Hobbs,et al. Adaptive adjustment of the randomization ratio using historical control data , 2013, Clinical trials.
[21] D J Spiegelhalter,et al. Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.
[22] D. Rubin,et al. Inference from Iterative Simulation Using Multiple Sequences , 1992 .
[23] Steven N Goodman,et al. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre , 2005, Clinical trials.
[24] Bill Ravens,et al. An Introduction to Copulas , 2000, Technometrics.
[25] Keming Yu,et al. Bayesian Mode Regression , 2012, 1208.0579.
[26] M. Daniels. A prior for the variance in hierarchical models , 1999 .
[27] D. Hatsukami,et al. Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[28] Ajay Jasra,et al. Markov Chain Monte Carlo Methods and the Label Switching Problem in Bayesian Mixture Modeling , 2005 .
[29] Michael A Proschan,et al. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. , 2016, The Journal of infectious diseases.
[30] Tony Tse,et al. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination , 2015, PloS one.
[31] P. Horby,et al. Randomised controlled trials for Ebola: practical and ethical issues , 2014, The Lancet.
[32] Brian Neelon,et al. Bayesian Analysis Using Power Priors with Application to Pediatric Quality of Care , 2010 .
[33] William J. Browne,et al. Bayesian and likelihood-based methods in multilevel modeling 1 A comparison of Bayesian and likelihood-based methods for fitting multilevel models , 2006 .
[34] Bradley P Carlin,et al. Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.
[35] Thierry Roncalli,et al. Which Copula is the Right One? , 2000 .
[36] Bradley P Carlin,et al. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.
[37] P. Green,et al. Reversible jump MCMC , 2009 .
[38] Arnovst Kom'arek,et al. Clustering for multivariate continuous and discrete longitudinal data , 2013, 1304.4448.
[39] P. Müller,et al. Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.
[40] B. Carlin,et al. Semiparametric Bayesian commensurate survival model for post‐market medical device surveillance with non‐exchangeable historical data , 2014, Biometrics.
[41] Karel G M Moons,et al. Incorporation of historical data in the analysis of randomized therapeutic trials. , 2011, Contemporary clinical trials.
[42] Jean-Michel Marin,et al. Bayesian Modelling and Inference on Mixtures of Distributions , 2005 .
[43] K. Karwowska,et al. Ebola virus disease , 2019, The Lancet.
[44] P. Thall,et al. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] J. Ioannidis,et al. Non-randomised Ebola trials--lessons for optimal outbreak research. , 2016, The Lancet. Infectious diseases.
[46] Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials , 2001 .
[47] P. Thall,et al. Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.
[48] Michael A Proschan,et al. Statistical considerations for a trial of Ebola virus disease therapeutics , 2016, Clinical trials.
[49] Jing Ning,et al. Response‐adaptive randomization for clinical trials with adjustment for covariate imbalance , 2010, Statistics in medicine.
[50] D. Spiegelhalter,et al. Summarizing historical information on controls in clinical trials , 2010, Clinical trials.
[51] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[52] D J Spiegelhalter,et al. Bayesian methods for cluster randomized trials with continuous responses. , 2001, Statistics in medicine.
[53] Adrian E. Raftery,et al. Bayesian Model Averaging: A Tutorial , 2016 .
[54] R. Kass,et al. Reference Bayesian Methods for Generalized Linear Mixed Models , 2000 .
[55] M. Steel,et al. Benchmark Priors for Bayesian Model Averaging , 2001 .
[56] J. Koopmeiners,et al. Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. , 2016, Addiction.
[57] D. Spiegelhalter,et al. Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .
[58] Joseph S Koopmeiners,et al. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. , 2018, Biostatistics.
[59] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[60] J. Koopmeiners,et al. Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. , 2016, Tobacco Regulatory Science.
[61] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[62] Adrian E. Raftery,et al. Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .
[63] Fulvio De Santis,et al. Power Priors and Their Use in Clinical Trials , 2006 .
[64] M. Stephens. Dealing with label switching in mixture models , 2000 .
[65] M. al’Absi,et al. Reduced Nicotine Content Cigarettes and Nicotine Patch , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[66] J. York,et al. Bayesian Graphical Models for Discrete Data , 1995 .
[67] Joseph G Ibrahim,et al. Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.
[68] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[69] A. Gelman. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .
[70] John M. Olin. Calculating posterior distributions and modal estimates in Markov mixture models , 1996 .
[71] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.